Imunoglukan Overview
- Founded
- 2010
- Status
- Private
- Employees
- 50
- Latest Deal Type
- Buyout/LBO
- Financing Rounds
- 1
Imunoglukan General Information
Description
Manufacturer of immunity focused dietary supplements. The company engages in research, development and sale of immunity medicines and dietary supplements, it manufactures imunoglukan which is a highly purified natural substance, , the compex of biologically active polysaccharides obtained through the isolation from Pleurotus ostreatus.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Primary Office
- Nové Záhrady I č. 13/A
- Bratislava, 821 05
- Slovakia
Imunoglukan Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Imunoglukan‘s full profile, request access.
Request a free trialImunoglukan Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Martin Polak | Chief Executive Officer | ||
| Ján Gabriž | Founder |
Imunoglukan Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialImunoglukan Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Imunoglukan‘s full profile, request access.
Request a free trial